{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Digestive+Disease&page=18", "query": { "condition": "Digestive Disease", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 14938, "total_pages": 1494, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Digestive+Disease&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Digestive+Disease&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T01:36:41.986Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00395018", "title": "Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis B, Chronic" ], "interventions": [ { "name": "entecavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 109, "start_date": "2007-04", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-05-31", "last_synced_at": "2026-10-23T01:36:41.986Z", "location_count": 9, "location_summary": "Chicago, Illinois • New Orleans, Louisiana • Rochester, Minnesota + 6 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00395018" }, { "nct_id": "NCT00003276", "title": "Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gallbladder Cancer" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1998-03", "completion_date": "2001-03", "has_results": false, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-10-23T01:36:41.986Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003276" }, { "nct_id": "NCT00130689", "title": "Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer", "Neoplasm Metastasis" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2005-07", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2015-05-14", "last_synced_at": "2026-10-23T01:36:41.986Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Peabody, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Peabody", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00130689" }, { "nct_id": "NCT07222189", "title": "A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colitis Ulcerative", "Crohn's Disease" ], "interventions": [ { "name": "balinatunfib", "type": "DRUG" }, { "name": "balinatunfib-matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "77 Years", "sex": "ALL", "summary": "19 Years to 77 Years" }, "enrollment_count": 7, "start_date": "2026-05-19", "completion_date": "2026-10-15", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-23T01:36:41.986Z", "location_count": 1, "location_summary": "Southlake, Texas", "locations": [ { "city": "Southlake", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07222189" }, { "nct_id": "NCT04585789", "title": "A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis B" ], "interventions": [ { "name": "JNJ-73763989", "type": "DRUG" }, { "name": "JNJ-56136379", "type": "DRUG" }, { "name": "Entecavir (ETV)", "type": "DRUG" }, { "name": "Tenofovir disoproxil", "type": "DRUG" }, { "name": "Tenofovir alafenamide (TAF)", "type": "DRUG" }, { "name": "PegIFN-alpha-2a (Optional)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2021-03-11", "completion_date": "2024-01-09", "has_results": true, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-10-23T01:36:41.986Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04585789" }, { "nct_id": "NCT03782376", "title": "A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Ustekinumab approximately 6 mg/kg (IV)", "type": "DRUG" }, { "name": "Placebo (SC)", "type": "DRUG" }, { "name": "Placebo (IV)", "type": "DRUG" }, { "name": "Ustekinumab 90 mg (SC) Group 1", "type": "DRUG" }, { "name": "Ustekinumab 90 mg (SC) Group 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen-Cilag Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 215, "start_date": "2018-12-20", "completion_date": "2023-01-10", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-23T01:36:41.986Z", "location_count": 28, "location_summary": "La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03782376" }, { "nct_id": "NCT03222076", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Resectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2017-09-28", "completion_date": "2022-09-14", "has_results": true, "last_update_posted_date": "2023-07-10", "last_synced_at": "2026-10-23T01:36:41.986Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03222076" }, { "nct_id": "NCT00241540", "title": "Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "GERD" ], "interventions": [ { "name": "Esomeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 808, "start_date": "2001-01", "completion_date": "2002-08", "has_results": false, "last_update_posted_date": "2011-01-24", "last_synced_at": "2026-10-23T01:36:41.986Z", "location_count": 19, "location_summary": "Tucson, Arizona • Anaheim, California • Orange, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00241540" }, { "nct_id": "NCT02952989", "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Renal Cell", "Breast Neoplasms", "Urinary Bladder Neoplasm", "Carcinoma, Squamous Cell of Head and Neck", "Colorectal Neoplasms", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "SGN-2FF", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2017-02-23", "completion_date": "2019-06-24", "has_results": false, "last_update_posted_date": "2019-07-19", "last_synced_at": "2026-10-23T01:36:41.986Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Duarte, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02952989" }, { "nct_id": "NCT04046068", "title": "Multimodal Perioperative Pain Management: ComfortSafe Program", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Post-operative Pain", "Post-operative Nausea and Vomiting", "Respiratory Depression", "Confusion Postoperative" ], "interventions": [ { "name": "ComfortSafe Care", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2020-05-11", "completion_date": "2021-09", "has_results": false, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-10-23T01:36:41.986Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04046068" } ] }